Target intelligence / Profile preview

RAD51-associated protein 1 (RAD51AP1)

Target
RAD51AP1
Molecular classification
DNA-binding protein, DNA repair protein, Homologous recombination accessory protein
01

Overview

RAD51-associated protein 1 is a structure-specific DNA-binding protein that facilitates homologous recombination by physically interacting with RAD51 and DNA intermediates, enhancing the RAD51-mediated formation of joint molecules (D-loops) during DNA repair. It possesses two distinct DNA-binding domains, both essential for its role in promoting efficient DNA repair and maintaining genome integrity. RAD51AP1 is required for cellular resistance to DNA double-strand breaks, operates both in somatic and meiotic recombination, and has a key role in alternative lengthening of telomeres in cancer cells. Mutations or dysregulation of RAD51AP1 are associated with genomic instability and disease, especially cancer and hereditary anemias[1][2][4].

Other names
PIR51HsRAD51AP1RAD51-interacting proteinRAD51AP1 proteinRAD51AP1 gene
02

Mechanism of action

Agents or molecules that inhibit RAD51AP1 function may impair homologous recombination repair, sensitize cancer cells to DNA-damaging agents, and promote genome instability. Synergistic action with other DNA repair homology-directed pathway components[2][4].

03

Biological functions

DNA repairHomologous recombinationDNA double-strand break repairPromotion of joint molecule (D-loop) formationChromosome damage repairMaintenance of genome integrity
04

Disease associations

Cancer (especially in the context of alternative lengthening of telomeres and genome instability in aggressive tumors)Aplastic anemiaFanconi anemiaOther disorders linked to homologous recombination deficiency
05

Safety considerations

Targeting RAD51AP1 or the homologous recombination pathway may induce genomic instability, cytotoxicity, or hypersensitivity to DNA damage in normal cellsPotential for bone marrow failure or tumorigenesis if repair is substantially disrupted
06

Interacting drugs

No clinically approved drugs directly target RAD51AP1 as of current literature; however, small molecules targeting homologous recombination (including RAD51-related pathways) are in research phases.
07

Biomarkers

No established clinical biomarkers for RAD51AP1 as a selection or efficacy marker; however, increased expression may serve as a research biomarker in cancer or DNA repair proficiency.

Beyond the preview

Go deeper on RAD51-associated protein 1 (RAD51AP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAD51-associated protein 1 (RAD51AP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call